









Markets
/
Stocks
/
nasdaq-lgnd
/

Ligand Pharmaceuticals Inc

LGND

169.830USD

+4.420+2.67%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

3.30BMarket Cap

LossP/E TTM



Ligand Pharmaceuticals Inc

169.830

+4.420+2.67%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

10 / 175

Overall Ranking

67 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

183.125

Target Price

+10.71%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 4.03M.%!(EXTRA int=2)

Undervalued

The company’s latest PE is -41.55, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 19.71M shares, decreasing 3.61% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.08M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.11.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 9.11, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 47.63M, representing a year-over-year increase of 14.68%, while its net profit experienced a year-over-year increase of 109.34%.

Score

Industry at a Glance

Previous score

9.11

Change



Financials

7.78

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.79

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -40.47, which is -207.27% below the recent high of 43.41 and 18.32% above the recent low of -33.05.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 10/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.57, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Ligand Pharmaceuticals Inc is 180.00, with a high of 206.00 and a low of 164.00.

Score

Industry at a Glance

Previous score

8.57

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

183.125

Target Price

+10.71%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Ligand Pharmaceuticals Inc

LGND

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 8.76, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 172.52 and the support level at 155.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.76

Change

0.24

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

-1.551

Neutral

RSI(14)

73.097

Buy

STOCH(KDJ)(9,3,3)

70.634

Buy

ATR(14)

4.036

High Vlolatility

CCI(14)

144.616

Buy

Williams %R

8.854

Overbought

TRIX(12,20)

0.510

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

166.549

Buy

MA10

166.379

Buy

MA20

163.876

Buy

MA50

149.173

Buy

MA100

128.992

Buy

MA200

120.655

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 102.13%, representing a quarter-over-quarter decrease of 0.67%. The largest institutional shareholder is The Vanguard, holding a total of 2.08M shares, representing 10.64% of shares outstanding, with 3.43% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.67M

-0.97%

The Vanguard Group, Inc.

Star Investors

2.05M

-1.44%

Janus Henderson Investors

1.03M

+1.23%

Macquarie Investment Management

906.23K

+2.47%

State Street Global Advisors (US)

727.13K

-2.22%

Dimensional Fund Advisors, L.P.

744.93K

+3.03%

Congress Asset Management Company, LLP

642.71K

+3.42%

Stephens Investment Management Group, LLC

607.22K

-0.91%

Chicago Capital, LLC

554.52K

+0.53%

Geode Capital Management, L.L.C.

464.45K

+5.93%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 5.60, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.